



Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

February 5, 2024

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference:

10th Annual Immuno-Oncology 360 Conference (IO360)

Speaker: Sergio Quezada, PhD, Chief Scientific Officer

Presentation: Targeting Clonal Neoantigens with Precision Cell Therapies

Location: New York Marriott at The Brooklyn Bridge, Brooklyn NY

Date: February 29, 2024

Time: 10:30am ET

For more information about IO360, please visit <https://io360summit.com>.

About Achilles Therapeutics

Achilles is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Investors:

Meru Advisors

Lee M. Stern

lstern@meruadvisors.com

Media:

ICR Consilium

Sukaina Virji, Tracy Cheung, Emmalee Hoppe

+44 (0) 203 709 5000

achillestx@consilium-comms.com